2006-004449-40: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or with Aspirin and a Thienopyridine in Subjects with Acute Coronary Syndromes (39039039ACS2001)The ATLAS ACS TIMI 46 Trial (Anti-Xa Therapy to Lower cardiovascular events in addition to Aspirin with or without thienopyridine therapy in Subjects with Acute Coronary Syndrome) |
|
|
| Completed | 2 | 6625 | Europe, RoW | Rivaroxaban, Aspirin, thienopyridine, BAY 59-7939 (JNJ-39039039), Film-coated tablet, Tablet | Bayer HealthCare AG, BAYER | Acute Coronary Syndrome | | | | |
ATLAS ACS TIMI 46, NCT00402597: Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The Trial) |
|
|
| Completed | 2 | 3490 | US | Rivaroxaban/Placebo, Placebo, Rivaroxaban | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Bayer | Acute Coronary Syndrome | 10/08 | 10/08 | | |
GEMINI ACS 1, NCT02293395 / 2014-004266-26: A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome |
|
|
| Completed | 2 | 3037 | Japan, US, Canada, Europe, RoW | Acetylsalicylic acid, Aspirin, Rivaroxaban, JNJ-39039039, Bay 59-7939, Xarelto, Clopidogrel, Plavix, Ticagrelor, Brilinta | Janssen Research & Development, LLC, Bayer, Duke Clinical Research Institute, Harvard Medical School (HMS and HSDM) | Acute Coronary Syndrome | 10/16 | 10/16 | | |
